Zihui Liu, Zong Wang, Linpin Liu, Bin Tu, Kai Wang
{"title":"Association of serum TIM-3 and Galectin-9 levels with glaucoma progression: implications for clinical monitoring.","authors":"Zihui Liu, Zong Wang, Linpin Liu, Bin Tu, Kai Wang","doi":"10.62347/HUVJ6501","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary open-angle glaucoma (POAG) causes irreversible blindness via retinal ganglion cell loss. Neuroinflammation and immune dysfunction drive its progression, yet the role of the TIM-3/Galectin-9 axis remains unclear.</p><p><strong>Objective: </strong>To investigate the association of serum soluble TIM-3 (sTIM-3) and Galectin-9 levels with the progression of primary open-angle glaucoma (POAG).</p><p><strong>Methods: </strong>This retrospective analysis enrolled POAG patients from our ophthalmology department (January 2022-December 2024). After a minimum 12-month follow-up, participants were categorized as progression or stable based on visual field and optical coherence tomography (OCT) assessments. Healthy controls were age/sex-matched. Recorded clinical variables included IOP, CCT, visual fields, and OCT measures. Baseline concentrations of sTIM-3 and Galectin-9 in serum were determined by ELISA. Multivariate logistic regression assessed independent links between these markers and disease progression, supplemented by trend tests, E-value calculations, and subgroup analyses.</p><p><strong>Results: </strong>The study included 120 POAG patients (52 progression, 68 stable) and 60 healthy controls. Baseline measures were balanced across groups. Both sTIM-3 and Galectin-9 were significantly elevated in progression relative to stable patients and controls (all P < 0.001). Multivariate logistic regression identified sTIM-3 (OR = 2.14, P = 0.004) and Galectin-9 (OR = 3.39, P < 0.001) as independent factors linked to disease progression. Trend analyses revealed dose-response patterns (P for trend = 0.015 and 0.004, respectively). These findings were further corroborated by E-value and subgroup analyses, supporting their robustness.</p><p><strong>Conclusions: </strong>Higher baseline sTIM-3 and Galectin-9 levels correlate independently with POAG progression risk, showing a dose-response pattern. These biomarkers may serve as adjunctive references for risk stratification, although their utility warrants prospective validation with longitudinal sampling.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7306-7319"},"PeriodicalIF":1.8000,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590988/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of translational research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/HUVJ6501","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Primary open-angle glaucoma (POAG) causes irreversible blindness via retinal ganglion cell loss. Neuroinflammation and immune dysfunction drive its progression, yet the role of the TIM-3/Galectin-9 axis remains unclear.
Objective: To investigate the association of serum soluble TIM-3 (sTIM-3) and Galectin-9 levels with the progression of primary open-angle glaucoma (POAG).
Methods: This retrospective analysis enrolled POAG patients from our ophthalmology department (January 2022-December 2024). After a minimum 12-month follow-up, participants were categorized as progression or stable based on visual field and optical coherence tomography (OCT) assessments. Healthy controls were age/sex-matched. Recorded clinical variables included IOP, CCT, visual fields, and OCT measures. Baseline concentrations of sTIM-3 and Galectin-9 in serum were determined by ELISA. Multivariate logistic regression assessed independent links between these markers and disease progression, supplemented by trend tests, E-value calculations, and subgroup analyses.
Results: The study included 120 POAG patients (52 progression, 68 stable) and 60 healthy controls. Baseline measures were balanced across groups. Both sTIM-3 and Galectin-9 were significantly elevated in progression relative to stable patients and controls (all P < 0.001). Multivariate logistic regression identified sTIM-3 (OR = 2.14, P = 0.004) and Galectin-9 (OR = 3.39, P < 0.001) as independent factors linked to disease progression. Trend analyses revealed dose-response patterns (P for trend = 0.015 and 0.004, respectively). These findings were further corroborated by E-value and subgroup analyses, supporting their robustness.
Conclusions: Higher baseline sTIM-3 and Galectin-9 levels correlate independently with POAG progression risk, showing a dose-response pattern. These biomarkers may serve as adjunctive references for risk stratification, although their utility warrants prospective validation with longitudinal sampling.